Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Osteoporosis

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 22 articles:
HTML format
Text format



Single Articles


    March 2018
  1. GOLLOGLY L, Norris S, Ford N
    Correcting the Record on a Fracture Risk Assessment Tool.
    N Engl J Med. 2018;378:867-868.
    PubMed     Text format    


    January 2018

  2. Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis.
    N Engl J Med. 2018;378:194-196.
    PubMed     Text format    


  3. TSOURDI E, Rachner TD, Hofbauer LC
    Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis.
    N Engl J Med. 2018;378:195.
    PubMed     Text format    


  4. LEWIS JR, Schousboe JT, Prince RL
    Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis.
    N Engl J Med. 2018;378:194-5.
    PubMed     Text format    


  5. SONG GG, Lee YH
    Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis.
    N Engl J Med. 2018;378:194.
    PubMed     Text format    


    October 2017
  6. ROSEN CJ
    Romosozumab - Promising or Practice Changing?
    N Engl J Med. 2017;377:1479-1480.
    PubMed     Text format    


    September 2017
  7. SAAG KG, Petersen J, Brandi ML, Karaplis AC, et al
    Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
    N Engl J Med. 2017 Sep 11. doi: 10.1056/NEJMoa1708322.
    PubMed     Text format     Abstract available


    May 2017
  8. ROCA-AYATS N, Balcells S, Garcia-Giralt N, Falco-Mascaro M, et al
    GGPS1 Mutation and Atypical Femoral Fractures with Bisphosphonates.
    N Engl J Med. 2017;376:1794-1795.
    PubMed     Text format    


    January 2017
  9. KALYAN SH
    Romosozumab Treatment in Postmenopausal Osteoporosis.
    N Engl J Med. 2017;376:395-6.
    PubMed     Text format    


  10. BANHIDY NF, MacKinnon TS, Banhidy FP
    Romosozumab Treatment in Postmenopausal Osteoporosis.
    N Engl J Med. 2017;376:395.
    PubMed     Text format    


  11. SHARMA R, Torka P
    Romosozumab Treatment in Postmenopausal Osteoporosis.
    N Engl J Med. 2017;376:395.
    PubMed     Text format    


  12. KRANENBURG G, Bartstra JW, de Jong PA
    Romosozumab Treatment in Postmenopausal Osteoporosis.
    N Engl J Med. 2017;376:396.
    PubMed     Text format    



  13. Romosozumab Treatment in Postmenopausal Osteoporosis.
    N Engl J Med. 2017;376:396-7.
    PubMed     Text format    


    September 2016
  14. ROSEN CJ, Ingelfinger JR
    Building Better Bones with Biologics - A New Approach to Osteoporosis?
    N Engl J Med. 2016.
    PubMed     Text format    


  15. COSMAN F, Crittenden DB, Adachi JD, Binkley N, et al
    Romosozumab Treatment in Postmenopausal Women with Osteoporosis.
    N Engl J Med. 2016.
    PubMed     Text format     Abstract available


    June 2016
  16. SIMSEK KIPER PO, Saito H, Gori F, Unger S, et al
    Cortical-Bone Fragility--Insights from sFRP4 Deficiency in Pyle's Disease.
    N Engl J Med. 2016;374:2553-62.
    PubMed     Text format     Abstract available


    May 2016
  17. CHEUNG AM, Papaioannou A, Morin S
    Postmenopausal Osteoporosis.
    N Engl J Med. 2016;374:2096.
    PubMed     Text format    


  18. OTT SM
    Postmenopausal Osteoporosis.
    N Engl J Med. 2016;374:2095-6.
    PubMed     Text format    


  19. MICHAELSSON K, Aspenberg P
    Postmenopausal Osteoporosis.
    N Engl J Med. 2016;374:2095.
    PubMed     Text format    


  20. BLACK DM, Rosen CJ
    Postmenopausal Osteoporosis.
    N Engl J Med. 2016;374:2096-7.
    PubMed     Text format    



  21. Postmenopausal Osteoporosis.
    N Engl J Med. 2016;374:1797.
    PubMed     Text format    


    January 2016
  22. BLACK DM, Rosen CJ
    Clinical Practice. Postmenopausal Osteoporosis.
    N Engl J Med. 2016;374:254-62.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Osteoporosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: